International Isotopes Inc. (INIS)
| Market Cap | 34.74M |
| Revenue (ttm) | 14.23M |
| Net Income (ttm) | 49.93K |
| Shares Out | 526.39M |
| EPS (ttm) | 0.00 |
| PE Ratio | 695.79 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,800 |
| Average Volume | 202,379 |
| Open | 0.0740 |
| Previous Close | 0.0720 |
| Day's Range | 0.0660 - 0.0740 |
| 52-Week Range | 0.0291 - 0.0840 |
| Beta | 0.86 |
| RSI | 60.74 |
| Earnings Date | Aug 13, 2025 |
About International Isotopes
International Isotopes Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE FIRST QUARTER 2025
Sale of product for first quarter increased 12% to $3.2 million. Nuclear Medicine Standards sale of product in the first quarter increased 73% to $1.3 million.
International Isotopes reports Q4 results
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2024
Revenues for fourth quarter increased 24% to $3.9 million. Full year revenues increased by 13% to $13.9 million, a historical high.
International Isotopes, Inc. Expands Operational Footprint with Strategic Land Acquisition and Additional New Facility Lease Agreement
IDAHO FALLS, Idaho , Jan. 13, 2025 /PRNewswire/ -- International Isotopes, Inc. (OTCQB: INIS) ("International Isotopes," "INIS" or the "Company"), is excited to announce a strategic expansion of its c...
International Isotopes announces an update to the acquisition of the AMICI product line
International Isotopes announces finalized acquisition agreement with AMICI, expanding their product line under the RadVent brand.
International Isotopes, Inc. Announces the Amendment of the Acquisition of the AMICI, Inc. Product Line
IDAHO FALLS, Idaho , Jan. 9, 2025 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) ("International Isotopes," "INIS" or the "Company") is pleased to announce that it has amended and finalized...
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF 2024
Company Revenues increased by over $1,000,000, or 34%, for the Third Quarter compared to the prior year Theranostics Sales increased 42% compared the Third Quarter in the prior year The Company report...
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE SECOND QUARTER AND FIRST SIX MONTHS OF 2024
Theranostics Sales increased 25% in the Second Quarter, and 16% for the Six Months Ended June 30, 2024 Gross Profit improved to 64%, a 7% increase, for the Six Months Ended June 30, 2024 Net Cash Prov...
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE FIRST QUARTER OF 2024
Theranostics Products Revenues Increased 8% in the Three Months Ended March 31, 2024; Net Cash Provided By Operating Activities Was Approximately $400,000 in the Three Months Ended March 31, 2024; Gro...
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR FISCAL YEAR 2023
Revenues Increased 10% in the Twelve Months Ended December 31, 2023 versus prior year Revenue of $12.3 million in the Twelve Months Ended December 31, 2023 was the highest in Company history Gross Pro...
INTERNATIONAL ISOTOPES TO DIVEST DEPLETED URANIUM DECONVERSION ASSETS TO AMERICAN FUEL RESOURCES FOR $12,500,000 CASH
IDAHO FALLS, Idaho , Feb. 8, 2024 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) ("International Isotopes," "INIS" or the "Company") is pleased to announce that it has entered into a defini...
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF 2023
Revenues Increased 14% in the Nine Months Ended September 30, 2023; Operating Loss Improved 43% in the Nine Months Ended September 30, 2023; and Gross Profit Increased 19% Nine Months Ended September ...
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE SECOND QUARTER AND FIRST SIX MONTHS OF 2023
Revenues Increased 28% in the Second Quarter; Net Cash Generation from Operations of more than $1,000,000 For The Six Months Ended June 30, 2023; June 30 th Cash Balance Remains In Excess Of $3,000,00...
INTERNATIONAL ISOTOPES INC. ANNOUNCES CHANGES IN EXECUTIVE OFFICERS AND DIRECTORS
Long Time Chief Executive Officer Steve Laflin Announced He Will Be Stepping Down September 1, 2023; Shahe Bagerdjian Appointed as CEO IDAHO FALLS, Idaho , July 18, 2023 /PRNewswire/ -- International ...
INTERNATIONAL ISOTOPES INC. ANNOUNCES THE ACQUISITION OF THE AMICI INC.
The Products Include All Molds, Manufacturing, And Registration Rights To AMICI's Leading Products, Including The "Swirler", "UltraShield", and "Tru-Fit" Mouth Piece IDAHO FALLS, Idaho , June 21, 2023...
INTERNATIONAL ISOTOPES INC. ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2023
The Company Reports A 10% Increase In Revenue Compared To The Same Period Last Year. This Is The Company's Highest Ever Recorded First Quarter Report IDAHO FALLS, Idaho , May 16, 2023 /PRNewswire/ -- ...
INTERNATIONAL ISOTOPES INC. ANNOUNCES THE APPOINTMENT OF SHAHE BAGERDJIAN AS PRESIDENT
IDAHO FALLS, Idaho , May 8, 2023 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) ("International Isotopes," "INIS" or the "Company") is pleased to announce that Shahe Bagerdjian has been app...
INTERNATIONAL ISOTOPES INC. ANNOUNCES 2022 YEAR END FINANCIAL RESULTS
The Company Reported A 16% Increase In Revenue to $11.2 Million In 2022 The Highest Single Year Revenue And Gross Profit In Company History Net Income Of Approximately $300,000 For The Year Year End C...
INTERNATIONAL ISOTOPES INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE-MONTHS 2022
The Company Reports A 9% Increase In Revenue For The First Nine-Months Of 2022, Compared To The Same Period In 2021, And A Net Profit Of Approximately $400,000 For The Year To Date. Cash Balance Remai...
INTERNATIONAL ISOTOPES INC. ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS OF 2022
The Company Reported A 10% Increase In Revenue And Net Income of more than $900,000 For The Six Months Ended June 30, 2022 IDAHO FALLS, Idaho , Aug. 16, 2022 /PRNewswire/ -- International Isotopes In...
INTERNATIONAL ISOTOPES INC. ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2022
The Company Reports A Net Profit Of Approximately $1.2 Million For The First Quarter And A 41% Increase In Revenue Compared To The Same Period Last Year IDAHO FALLS, Idaho , May 17, 2022 /PRNewswire/ ...
INTERNATIONAL ISOTOPES INC. ANNOUNCES 2021 YEAR END FINANCIAL RESULTS
The Company Reported Increased Sales In All Business Segments and a 3% Overall Increase In Revenue For 2021 Compared to 2020 IDAHO FALLS, Idaho , April 4, 2022 /PRNewswire/ -- International Isotopes I...
INTERNATIONAL ISOTOPES INC. ANNOUNCES COMPLETION OF AN ASSET PURCHASE AGREEMENT WITH PHARMALOGIC HOLDINGS CORP.
IDAHO FALLS, Idaho, Feb. 22, 2022 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) ("International Isotopes" or "INIS") is pleased to announce it has completed an asset purchase agreement wit...
INTERNATIONAL ISOTOPES INC. ANNOUNCES COMPLETION OF A MODIFICATION TO EXTEND THE MATURITY DATE OF ITS SERIES C PREFERRED STOCK
IDAHO FALLS, Idaho, Feb. 17, 2022 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) ("International Isotopes" or "INIS") has announced the completion of a modification to the term of its Serie...
International Isotopes Inc. Announces Exclusive Licensing Agreement For Commercialization Of A Radiolabled Antibody Test For Detecting SARS CoV-2
IDAHO FALLS, Idaho, Dec. 7, 2021 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) ("International Isotopes" or "INIS") is pleased to announce updated information regarding research it has bee...